| Identification | Back Directory | [Name]
3-Thiazolidinecarboxamide, N-(3,4-dichlorophenyl)-2-[(4-fluorophenyl)imino]-5-methyl- | [CAS]
2411853-34-2 | [Synonyms]
3-Thiazolidinecarboxamide, N-(3,4-dichlorophenyl)-2-[(4-fluorophenyl)imino]-5-methyl- | [Molecular Formula]
C17H14Cl2FN3OS | [MOL File]
2411853-34-2.mol | [Molecular Weight]
398.28 |
| Chemical Properties | Back Directory | [density ]
1.45±0.1 g/cm3(Predicted) | [solubility ]
Ethanol:3.0(Max Conc. mg/mL);7.53(Max Conc. mM) | [form ]
Solid | [pka]
11.58±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [in vivo]
Mice were subcutaneously implanted with tumor cells and when tumors were palpable (~200 mm3), mice were randomized into treatment groups receiving vehicle, JR-AB2-011 (4 mg/kg/d) and JR-AB2-011 (20 mg/kg/d). As shown in Fig 6A, mice receiving JR-AB2-011 at either dosing regimen displayed marked inhibition of tumor growth rate (JR-AB2-011 at 4 mg/kg/d; 74% inhibition at end of dosing period; tumor growth delay 10.0 days; JR-AB2-011 at 20 mg/kg/d; 80% inhibition at end of dosing period; tumor growth delay 12.0 days) as compared to mice receiving vehicle alone. Consistent with the effects on xenograft growth, overall survival of mice at either JR-AB2-011 dosing regimen was significantly extended relative to vehicle treated mice. _x000D_
_x000D_
Reference: PLoS One. 2017 Apr 28;12(4):e0176599. https://pubmed.ncbi.nlm.nih.gov/28453552/ | [target]
JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM). |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|